What Selexis does

Selexis is a privately held Swiss life sciences company founded in 2001 and headquartered in Plan-les-Ouates, Switzerland, with 11-50 employees. The company develops proprietary mammalian (CHO-based) cell line technology for biologics manufacturing, centered on a semitargeted transgene integration approach using a transposon system. Its core assets include the SUREtechnology Platform, the SURE CHO-M Cell Line, and the SUREmAb monoclonal antibody solution, the last of which compresses DNA-to-GMP timelines to 11 months and was launched commercially in September 2023 via KBI Biopharma. Selexis also has an E. coli expression platform (PUREplatform / PUREcoli) operating alongside its CHO franchise.

Commercially, Selexis operates as a technology licensor and integration partner rather than a standalone CDMO. Its SUREtechnology Platform is embedded into KBI Biopharma, a JSR Life Sciences subsidiary, and is branded as "powered by Selexis." Revenue is therefore driven primarily by technology licensing and integration into KBI's mammalian CDMO programs, supplemented by grant funding such as the 2002 Foundation for Innovation and Technology (FIT) seed award and a 2015 Eurostars program. The company supports biologics developers working on monoclonal antibodies and complex antibody derivatives (ADCs, bispecific antibodies, Fc fusion proteins), which represent roughly half of KBI's project pipeline and which depend on the consistency and predictability advantages of Selexis's CHO cell line technology.

Selexis has signaled forward-looking R&D priorities, including AI-driven scale-up prediction and development of a viral-free CHO cell line to anticipate future regulatory requirements. Its commercial footprint is supported by senior leadership including a CFO (Alberto Garotti), CSO (Pierre-Alain Girod), COO (Regine Brokamp), and two VPs of Licensing and Business Development (Marco Bocci and Yemi Onakunle), pointing to a strategy that combines proprietary technology development with out-licensing and partnership expansion within the broader JSR Life Sciences ecosystem and potentially beyond.

Name

Selexis

Legal name

KBI Biopharma

Website

https://selexis.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Short description

Selexis is a Swiss life sciences company (founded 2001, 11-50 employees) that develops proprietary CHO-based mammalian cell line technology using semitargeted transgene integration, commercially deployed through KBI Biopharma and JSR Life Sciences for biologics manufacturing.

Ownership category

akta.pro rank

Headquarters

HQ city

Plan-les-ouates

HQ country

Switzerland

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Fee-for-service contract development and manufacturing organization (CDMO) providing end-to-end services for biologics development. Services include cell line development, process development, analytical development, formulation development, characterization, clinical manufacturing, and commercial manufacturing for mammalian and microbial modalities. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Selexis provides proprietary cell line development technology and platforms for the biopharmaceutical industry. Its core offering is the SUREtechnology Platform™ — a CHO-based mammalian cell line development system powered by Selexis® that delivers stable, high-yield production of complex biologics including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and Fc fusion proteins. Selexis also provides the SURE CHO-M Cell Line™ and enables accelerated monoclonal antibody development timelines via SUREmAb™.

Product overview

KBI Biopharma operates as a Contract Development and Manufacturing Organization (CDMO) providing comprehensive services for complex biologics development and manufacturing. The company offers integrated platforms and services including the SUREtechnology Platform™ (powered by Selexis®) for CHO-based mammalian cell line development, the PUREplatform™ for E. coli microbial expression, and comprehensive analytical and manufacturing services. The technology portfolio includes SURE CHO-M Cell Line™, SUREmAb™, PUREcoli™, and PROGRAMview™ digital solutions, supporting clients from cell line development through commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• SUREtechnology Platform™: Powered by Selexis® for premium, stable, and integrated CHO-based cell line development. Versatile, scalable, and efficient.
• SURE CHO-M Cell Line™
• SUREmAb™
• PUREplatform™
• PUREcoli™
• PROGRAMview™

Products and services

• SUREtechnology Platform™ A premium, stable, and integrated CHO-based cell line development platform powered by Selexis® that provides versatile, scalable, and efficient mammalian expression for complex biologics including monoclonal antibodies, ADCs, bispecific antibodies, and Fc fusion proteins. Licensed to biopharma and CDMO partners for therapeutic protein production.
• SURE CHO-M Cell Line™ A proprietary Chinese Hamster Ovary (CHO) cell line developed by Selexis and used within the SUREtechnology Platform. It employs semitargeted transgene integration using a transposon system to enable stable, high-yield production of complex biologics including monoclonal antibodies, ADCs, bispecifics, and Fc fusion proteins.
• SUREmAb™ A monoclonal antibody development solution built on Selexis's SUREtechnology Platform that compresses development timelines from DNA to GMP drug substance to 11 months, accelerating biologic development programs for biopharmaceutical clients.

Quantifiable outcome

• 11 months from DNA to GMP drug substance
• +1 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• SelexiscoreTechnology or IntegrationKBI Biopharma's SUREtechnology Platform is powered by Selexis technology for premium, stable, and integrated CHO-based cell line development. This technology integration provides the foundation for KBI's mammalian cell line development services, enabling versatile, scalable, and efficient production of complex biologics.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• KBI Biopharma: Sister CDMO under JSR Life Sciences and named commercial channel for Selexis' SUREtechnology Platform; the tightest direct comparable because Selexis' tech is functionally embedded in KBI's mammalian cell-line development offering.
• Lonza Biologics: Large-scale CDMO with proprietary GS Xceed mammalian cell-line platform and Ibex suite for biologics manufacturing; the most direct alternative to Selexis' CHO-based cell-line development for global biopharma clients.
• Boehringer Ingelheim BioXcellence: BI's biopharmaceutical contract manufacturing arm offering proprietary CHO-based cell line development (BI-HEX) end-to-end; competes head-on with Selexis in mammalian upstream and commercial supply.
• Catalent Biologics: Mammalian and microbial biologics CDMO with GPEx cell-line technology; offers a comparable upstream technology-licensing/Cell-Line-Dev product that overlaps with SUREtechnology for monoclonal antibody and recombinant protein developers.

Broad incumbents

• Samsung Biologics: Large Korean CDMO with end-to-end cell-line to commercial biologics services including its own S-CHOice platform; represents the scaled integrated alternative that can disintermediate Selexis' standalone tech model.
• AGC Biologics: Global CDMO offering mammalian and microbial cell-line development and GMP manufacturing under multiple legacy brands (Cobra, Molecular Partners); broad incumbent serving the same complex-biologics buyer that Selexis targets.
• WuXi Biologics: Chinese CDMO with proprietary cell-line construction capabilities and one of the largest biologics manufacturing footprints; comparable in function but competes primarily on cost and scale.
• Thermo Fisher Scientific (Patheon CDMO): Global CDMO/biologics services provider including cell-line development under its pharma services umbrella; broad incumbent with the breadth to absorb upstream cell-line work that would otherwise go to Selexis.

Emerging players

• ATUM (now part of PharmaBio): Synthetic biology and protein-engineering company with its own Leap-In transposase-based cell-line platform; emerging niche competitor to SUREtechnology's semitargeted transgene integration approach.

Others

• Revvity (formerly Horizon Discovery): Cell-line engineering and cell-based screening specialist supplying CHO and other engineered cell lines plus gene-editing tools; adjacent ecosystem player whose products enable the same biologic-development workflows Selexis serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/selexissa
• Facebookfacebook.com/SelexisSA
• LinkedInlinkedin.com/company/selexis-sa

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Selexis